Lyka Labs Limited has announced a crucial board meeting scheduled for September 29, 2025, to address significant corporate matters. The pharmaceutical company's Board of Directors is set to convene and deliberate on several key issues that could impact its financial structure and corporate governance.

Preference Share Redemption

One of the primary agenda items for the meeting is the consideration of redeeming 1,08,570 unlisted 10% Cumulative Redeemable Preference Shares. These shares, valued at Rs.100 each, represent a total redemption value of approximately Rs.1.09 crore. This move, if approved, could potentially affect the company's capital structure and signal a strategic financial decision.

Appointment of Key Personnel

The board will also discuss the appointment of a Company Secretary and Compliance Officer. This position is crucial for ensuring adherence to regulatory requirements and maintaining effective corporate governance practices. The appointment could strengthen Lyka Labs' compliance framework and investor relations.

Additional Business Matters

While the preference share redemption and key appointment are the highlighted items, the board meeting will also address other business matters. The nature of these additional items has not been specified in the announcement.

Regulatory Compliance

In line with regulatory requirements, Lyka Labs has duly informed both the BSE (Bombay Stock Exchange) and NSE (National Stock Exchange) about the upcoming board meeting and its agenda. This transparency aligns with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Management Statement

Yogesh Shah, Whole-time Director and CFO of Lyka Labs Limited, signed the official intimation of the board meeting. The company has also made this information available on its website, www.lykalabs.com , ensuring easy access for all stakeholders.

Investors and market watchers will likely keep a close eye on the outcomes of this board meeting, particularly regarding the potential redemption of preference shares and the appointment of key personnel. These decisions could have implications for Lyka Labs' financial strategy and corporate structure going forward.

Lyka Labs Limited has provided an update on its ongoing amalgamation process with Lyka Exports Limited, revealing a slight delay in the proceedings. The National Company Law Tribunal (NCLT), Ahmedabad Bench, has requested additional information from the Income Tax Department before moving forward with the case.

NCLT Directs Income Tax Department to Submit Report

According to the latest intimation from Lyka Labs, the NCLT has directed the Income Tax Department to submit its report within seven days regarding the joint petition filed by both Lyka Labs and Lyka Exports. This development comes after the NCLT had previously reserved the matter for formal pronouncement, indicating 'no objection' in due course.

Timeline of Events

• 8th August: Lyka Labs informed stakeholders that the joint petition for the Scheme of Amalgamation was reserved by the NCLT for formal pronouncement.
• 17th September: The NCLT directed the Income Tax Department to submit its report within seven days.
• 18th September: Lyka Labs issued an intimation to the stock exchanges regarding the NCLT's latest directive.
• 9th October: The case is scheduled for further consideration by the NCLT.

Implications for Shareholders

While the request for an Income Tax Department report introduces a short delay in the amalgamation process, it appears to be a standard procedural step. Shareholders and investors of both Lyka Labs and Lyka Exports should note that this development is part of the due diligence process typically associated with corporate amalgamations.

Company's Transparency

Lyka Labs has maintained transparency throughout the amalgamation process, promptly informing the stock exchanges and shareholders about the developments. The company has made the information available on its website ( www.lykalabs.com ) for easy access by stakeholders.

Looking Ahead

The market will be closely watching the outcome of the NCLT's consideration on October 9. This date could potentially bring more clarity on the progress of the amalgamation scheme between Lyka Labs and Lyka Exports.

Investors and interested parties are advised to keep an eye on further announcements from the company as the amalgamation process moves forward.